Stay tuned, leave your email
Articles récents
- Videoconference • Annual Results 2024-25
- Press Release: Consolidated Annual Financial Results
- Truist Securities Initiates Medincell’s Coverage with a “Buy” Recommendation
- UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025
- Medincell and iM4TB Join Forces to Fight Tuberculosis
Commentaires récents
No comments to show.
